Amgen today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity.
Amgen's expansion of its biologics manufacturing facility in Puerto Rico will strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs. The company said its Juncos site, established in 1992, is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to more than 60 countries.
Amgen's latest investment builds on its broader U.S. manufacturing expansion strategy. Over the past year, the company has announced planned investments of $650 million in Puerto Rico, $900 million in Ohio and $600 million in a science and innovation center in California. In addition, Amgen has invested more than $1.5 billion in North Carolina.
"This investment confirms that the policies we have implemented are working. Puerto Rico has more than 60 years of excellence in the biopharmaceutical sector, supported by a highly skilled workforce and world‑class infrastructure, and Amgen knows this better than anyone," said Puerto Rico Governor Jenniffer González Colón. "We will continue working to make Puerto Rico the number one destination for advanced manufacturing in the United States."
